drugset
drugset / Trial / NCT04653168

A Study of LY3041658 in Healthy Participants

NCT04653168 ↗

Phase 1 Completed 16 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3041658 in healthy participants. The study will measure how the body absorbs, breaks down and gets rid of LY3041658.

Timeline

Start
2020-12-07
Primary completion
2021-05-28
Completion
2021-05-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Eltrekibart Monoclonal antibody — Subcutaneous

Indications

No indication recorded.